Published in N Engl J Med on November 28, 1974
Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev (2007) 3.18
Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother (1992) 1.80
Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies. Antimicrob Agents Chemother (2000) 1.76
Antibacterial activity of cinoxacin in vitro. Antimicrob Agents Chemother (1975) 1.50
Urinary tract infections in the elderly. Bull N Y Acad Med (1980) 1.35
Comparison of pharmacological and antimicrobial properties of cefadroxil and cephalexin. Antimicrob Agents Chemother (1977) 1.08
Efficacy of cinoxacin in urinary tract infections. Antimicrob Agents Chemother (1976) 1.01
Outcomes of Aminopenicillin Therapy for Vancomycin-Resistant Enterococcal Urinary Tract Infections. Antimicrob Agents Chemother (2015) 1.00
Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers. Antimicrob Agents Chemother (1996) 0.99
Urinary Tract Infections: Resistance Is Futile. Antimicrob Agents Chemother (2016) 0.96
Concentration of amoxycillin and clavulanate in lung compartments in adults without pulmonary infection. Thorax (1994) 0.95
Management of uncomplicated urinary tract infections. West J Med (2002) 0.95
Antibiotic penetration into lung tissues. Thorax (1994) 0.94
Experimental studies of biliary excretion of piperacillin. Ann Surg (1987) 0.82
Oral doxycycline for non-systemic urinary tract infections (UTIs) due to P. aeruginosa and other Gram negative uropathogens. Eur J Clin Microbiol Infect Dis (2012) 0.81
Chronic Salmonella bacteriuria with intermittent bacteremia treated with low doses of amoxicillin or ampicillin. Antimicrob Agents Chemother (1981) 0.81
An infectious disease and pharmacokinetic perspective on oral antibiotic treatment of uncomplicated urinary tract infections due to multidrug-resistant Gram-negative uropathogens: the importance of urinary antibiotic concentrations and urinary pH. Eur J Clin Microbiol Infect Dis (2016) 0.79
In vitro activity of spectinomycin against recent urinary tract isolates. Antimicrob Agents Chemother (1977) 0.77
Suspicion of quinolone active metabolite following discrepancy between predicted and experimental urine bactericidal activities. Antimicrob Agents Chemother (1997) 0.76
Cephalosporins in urinary tract infection. Drugs (1987) 0.75
Risk Factor Analysis of Ciprofloxacin-Resistant and Extended Spectrum Beta-Lactamases Pathogen-Induced Acute Bacterial Prostatitis in Korea. J Korean Med Sci (2016) 0.75
Editorial: urinary tract infection. Can Med Assoc J (1975) 0.75
Kinetics and dynamics of tobramycin action in patients with bacteriuria given single doses. Antimicrob Agents Chemother (1991) 0.75
Pharmacodynamic evaluation of fosfomycin against E. coli and Klebsiella spp. from urinary tract infections and the influence of pH on fosfomycin activities. Antimicrob Agents Chemother (2017) 0.75
Nitrofurantoin safety and effectiveness in treating acute uncomplicated cystitis (AUC) in hospitalized adults with renal insufficiency: antibiotic stewardship implications. Eur J Clin Microbiol Infect Dis (2017) 0.75
Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med (1987) 6.41
Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol (1968) 5.98
Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 4.05
Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys (1998) 3.82
Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol (1989) 3.78
Antibacterial nature of prostatic fluid. Nature (1968) 3.68
Recurrent urinary infections in adult women. The role of introital enterobacteria. Calif Med (1971) 3.32
Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol (1988) 3.20
Studies of introital colonization in women with recurrent urinary infections. VII. The role of bacterial adherence. J Urol (1977) 3.20
Classification of benign diseases associated with prostatic pain: prostatitis or prostatodynia? J Urol (1978) 2.74
Genetic alterations in bladder cancer. Lancet (1993) 2.73
Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst (1995) 2.70
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol (1993) 2.42
Resistance to nalidixic acid. A misconception due to underdosage. JAMA (1976) 2.31
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res (1993) 2.22
Diffusion of antibiotics from plasma into prostatic fluid. Nature (1968) 2.18
The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol (1997) 2.13
Endoscopic suspension of the vesical neck for urinary incontinence. Surg Gynecol Obstet (1973) 2.06
Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol (1989) 2.06
Expression of the prostate-specific membrane antigen. Cancer Res (1994) 2.06
The TNM classification of prostate cancer. Prostate Suppl (1992) 1.96
Adult urological sarcoma. J Urol (1992) 1.94
Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol (1997) 1.93
Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol (1998) 1.88
Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res (1994) 1.85
Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst (1992) 1.81
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol (1994) 1.78
Development and progression of clubbing and scarring in children with recurrent urinary tract infections. Radiology (1974) 1.78
Patterns of progression in prostate cancer. Lancet (1986) 1.78
The role of vaginal colonization with enterobacteriaceae in recurrent urinary infections. J Urol (1975) 1.77
The histology of interstitial cystitis. Am J Surg Pathol (1990) 1.75
The periurethral glands do not significantly influence the serum prostate specific antigen concentration. J Urol (1996) 1.73
Endoscopic sphincterotomy for bile duct stones in patients with intact gallbladders. Br J Surg (1989) 1.73
Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol (1995) 1.71
Chronic bacterial prostatitis and the diffusion of drugs into prostatic fluid. J Urol (1970) 1.69
Determination of prostate volume by transrectal ultrasound. J Urol (1991) 1.69
Prostatitis. J R Soc Med (1981) 1.64
Comparison of mid-lobe versus lateral systematic sextant biopsies in the detection of prostate cancer. Urol Int (1997) 1.60
Histopathological, cytogenetic, and molecular characterization of renal cortical tumors. Cancer Res (1991) 1.59
The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys (1991) 1.58
Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol (1998) 1.53
The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol (1994) 1.53
Prostate cancer: emerging concepts. Part I. Ann Intern Med (1996) 1.51
Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol (1992) 1.50
Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. J Clin Oncol (1996) 1.49
Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Br J Urol (1996) 1.45
Endoscopic suspension of the vesical neck for urinary incontinence in females. Report on 203 consecutive patients. Ann Surg (1980) 1.45
Prophylactic efficacy of nitrofurantoin macrocrystals and trimethoprim-sulfamethoxazole in urinary infections. Biologic effects on the vaginal and rectal flora. N Engl J Med (1977) 1.44
The diffusion and concentration of trimethoprim in human vaginal fluid. J Infect Dis (1975) 1.44
Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res (1995) 1.43
Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst (1993) 1.42
Association of the Lewis blood-group phenotype with recurrent urinary tract infections in women. N Engl J Med (1989) 1.42
Assessment of morphometric measurements of prostate carcinoma volume. Cancer (2000) 1.42
The role of perineural space invasion in the local spread of prostatic adenocarcinoma. J Urol (1989) 1.40
Interstitial cystitis: early diagnosis, pathology, and treatment. Urology (1978) 1.40
The central role of prostate specific antigen in diagnosis and progression of prostate cancer. J Urol (1995) 1.40
Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer (1990) 1.40
Comparison of prostate size in university and Veterans Affairs Health Care System patients with negative prostate biopsies. Urology (1998) 1.39
Effect of flutamide and flutamide plus castration on prostate size in patients with previously untreated prostate cancer. Urology (1996) 1.38
Diffusion of sulfonamides from plasma into prostatic fluid. J Urol (1970) 1.38
Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res (1991) 1.36
Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer (1992) 1.34
Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res (1994) 1.34
Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res (1994) 1.33
Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res (1985) 1.32
Nerve sparing radical prostatectomy: a different view. J Urol (1995) 1.32
Prostatic antibacterial factor. Identity and significance. Urology (1976) 1.30
The immunologic basis of recurrent bacteriuria: role of cervicovaginal antibody in enterobacterial colonization of the introital mucosa. Medicine (Baltimore) (1978) 1.29
Clinical and laboratory studies into the pathogenesis of malacoplakia. J Clin Pathol (1976) 1.27
Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab (1993) 1.26
Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res (1989) 1.22
Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol (1994) 1.21
Clinical and roentgenographic evaluation of endoscopic suspension of the vesical neck for urinary incontinence. Surg Gynecol Obstet (1975) 1.19
Urinary tract infections in children. Part I-- Young girls with non-refluxing ureters. West J Med (1974) 1.18
Persistent membrane translocation of protein kinase C alpha during 12-0-tetradecanoylphorbol-13-acetate-induced apoptosis of LNCaP human prostate cancer cells. Cell Growth Differ (1996) 1.17
An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. J Urol (2000) 1.16
Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J Urol (1999) 1.14
Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol (1997) 1.14
Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients. J Urol (1996) 1.13
Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers. J Urol (2000) 1.13
Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer (1993) 1.13
Bacteriologic and hormonal observations of the urethra and vaginal vestibule in normal, premenopausal women. J Urol (1970) 1.12
Observations on the clinical use of nalidixic acid. Postgrad Med J (1971) 1.12
Abbott IMx evaluated for assay of prostate-specific antigen in serum. Clin Chem (1992) 1.12
Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate (1995) 1.11
Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers. J Urol (1996) 1.11
The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer (1987) 1.10